On Friday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) was -3.08% drop from the session before settling in for the closing price of $13.63. A 52-week range for KALV has been $7.30 – $16.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -17.63% over the past five years. When this article was written, the company’s average yearly earnings per share was at 8.75%. With a float of $38.59 million, this company’s outstanding shares have now reached $49.76 million.
Let’s look at the performance matrix of the company that is accounted for 270 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward KalVista Pharmaceuticals Inc stocks. The insider ownership of KalVista Pharmaceuticals Inc is 22.75%, while institutional ownership is 88.26%. The most recent insider transaction that took place on Jul 09 ’25, was worth 517,523. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 32,979 shares at a rate of $15.69, taking the stock ownership to the 369,595 shares. Before that another transaction happened on Jul 09 ’25, when Company’s CHIEF DEVELOPMENT OFFICER sold 30,250 for $15.69, making the entire transaction worth $474,698. This insider now owns 127,939 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 8.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 56.58% during the next five years compared to -17.63% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
You can see what KalVista Pharmaceuticals Inc (KALV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -2.16 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
KalVista Pharmaceuticals Inc (NASDAQ: KALV) saw its 5-day average volume 1.08 million, a positive change from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 11.10%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 56.14%, which indicates a significant increase from 0.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.70 in the past 14 days, which was lower than the 0.77 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.42, while its 200-day Moving Average is $11.32. Nevertheless, the first resistance level for the watch stands at $13.63 in the near term. At $14.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.27. If the price goes on to break the first support level at $12.99, it is likely to go to the next support level at $12.77. The third support level lies at $12.35 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
There are 49,954K outstanding shares of the company, which has a market capitalization of 659.89 million. As of now, sales total 0 K while income totals -183,440 K. Its latest quarter income was 0 K while its last quarter net income were -52,220 K.
